Kalevi Reijonen appointed as CEO & President of
FIT Biotech
November 27 2003, Press release
Kalevi Reijonen has been appointed as new CEO & President of FIT Biotech Plc with effect from 1st of March 2004. Dr. Reijonen has over 28 years of experience from pharmaceutical and biotechnology industries. He has previously held a number of international positions in marketing and business development with the Orion Pharmaceuticals Group. Dr. Reijonen joins FIT Biotech on December 1st , 2003.
About FIT Biotech
FIT Biotech Plc is an innovative medical biotechnology company engaged in the development and commercialization of its proprietary Gene Transport Unit (GTU®) technology and GTU product applications in DNA vaccination and immune therapy. The company’s other areas of expertise are artificial immunogen (multiepitope), recombinant protein and antibody technologies, as well as GMP grade process development and production of DNA vaccines. In addition, the company has developed and launched diagnostic products for the detection of natural latex allergens. FIT Biotech was established in 1995 and is located in Tampere, Finland, with operations also in Tartu, Estonia.
Further information
Chairman of the Board of Directors Rabbe Slätis
GSM +358 40 840 6749
rabbe.slatis@karyon.fi
E-mail
